Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478565 | 0.89 | CYP2A6 (0.51) | ERN1CYP2A6ALDH1A1MAPTRAB9A | |
| SCHEMBL7105039 | 0.86 | MAPT (0.60) | CYP2A6ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6488126 | 0.80 | PSMB8 (0.50) | ERN1CYP2A6ALDH1A1MAPTRAB9A | |
| SCHEMBL6609540 | 0.78 | HDAC6 (0.48) | ERN1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL18003143 | 0.75 | PGR (0.57) | CYP2A6ALDH1A1KDM4ECA12CA1 | |
| SCHEMBL6488298 | 0.74 | ALOX15 (0.48) | ALDH1A1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL6488302 | 0.74 | ALOX15 (0.48) | ALDH1A1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL6488293 | 0.74 | ALOX15 (0.48) | ALDH1A1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL6485304 | 0.73 | TNKS (0.57) | ALDH1A1MAPTRAB9ASMN1; SMN2TP53 | |
| SCHEMBL4399339 | 0.73 | KDM4E (0.72) | ERN1ALDH1A1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780859-B2 | FOR THERAPY OF DIABETES, OBESITY, IMPAIRED GLUCOSE TOLERANCE, GASTROINTESTINAL DISORDERS, HYPERTRIGLYCERIDEMIA, HYPERCHOLESTEOLEMIA, ATHEROSCLEROTIC DISORDERS, OR CARDIOVASCULAR DISORDERS | BAYER PHARMACEUTICALS CORPORATION | 2004-08-24 | — | — | US | disclosed |
| EP-1430043-A1 | BENZOFURAN AND DIHYDROBENZOFURAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Pharmaceuticals Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030195352-A1 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-10-16 | — | — | US | disclosed |
| WO-2003024948-A1 | BENZOFURAN AND DIHYDROBENZOFURAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195352-A1 | Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | ERN1 3499/4885CYP2A6 1679/4885ALDH1A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.